Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewSKF 38393 hydrobromide
Description: Selective D1-like agonist
Chemical Name: (±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol hydrobromide
Purity: ≥98% (HPLC)
Biological Activity for SKF 38393 hydrobromide
SKF 38393 hydrobromide is a prototypical D1-like dopamine receptor selective partial agonist (Ki values are 1, ~ 0.5, ~ 150, ~ 5000 and ~ 1000 nM for D1, D5, D2, D3 and D4 receptors respectively).
Compound Libraries for SKF 38393 hydrobromide
SKF 38393 hydrobromide is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
Technical Data for SKF 38393 hydrobromide
| M. Wt | 336.23 |
| Formula | C16H17NO2.HBr |
| Storage | Desiccate at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 20012-10-6 |
| PubChem ID | 12928470 |
| InChI Key | INNWVRBZMBCEJI-UHFFFAOYSA-N |
| Smiles | Br.OC1=CC2=C(C=C1O)C(CNCC2)C1=CC=CC=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for SKF 38393 hydrobromide
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 8.41 | 25 with gentle warming | |
| DMSO | 33.62 | 100 |
Preparing Stock Solutions for SKF 38393 hydrobromide
The following data is based on the product molecular weight 336.23. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.97 mL | 14.87 mL | 29.74 mL |
| 5 mM | 0.59 mL | 2.97 mL | 5.95 mL |
| 10 mM | 0.3 mL | 1.49 mL | 2.97 mL |
| 50 mM | 0.06 mL | 0.3 mL | 0.59 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for SKF 38393 hydrobromide
References for SKF 38393 hydrobromide
References are publications that support the biological activity of the product.
Geter-Douglass et al (1997) Characterization of unconditioned behavioral effects of DA D3/D2 receptor agonists. J.Pharmacol.Exp.Ther. 283 7 PMID: 9336302
Habuchi et al (1997) DA stimulation of cardiac β-adrenoceptors: the involvement of sympathetic amine transporters and the effect of SKF38393. Br.J.Pharmacol. 122 1669 PMID: 9422813
Seeman and Van Tol (1994) DA receptor pharmacology. TiPS 15 264 PMID: 7940991
Sibley et al (1982) Interactions of novel DArgic ligands with D1 and D2 DA receptors. Life Sci. 31 637 PMID: 6127585
If you know of a relevant reference for SKF 38393 hydrobromide, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: SKF 38393 hydrobromide, SKF 38393 hydrobromide supplier, Selective, D1-like, agonists, Dopamine, D1, Receptors, D5, dopaminergic, SKF38393, hydrobromide, and, 0922, Tocris Bioscience
18 Citations for SKF 38393 hydrobromide
Citations are publications that use Tocris products. Selected citations for SKF 38393 hydrobromide include:
Tozzi et al (2015) Endogenous 17β-OE is required for activity-dependent long-term potentiation in the striatum: interaction with the DArgic system. Front Cell Neurosci 9 192 PMID: 26074768
Grochowska et al (2017) Posttranslational modification impact on the mechanism by which amyloid-β induces synaptic dysfunction. EMBO Rep 18 962 PMID: 28420656
Moreno et al (2014) Cocaine disrupts histamine H3 receptor modulation of DA D1 receptor signaling: σ1-D1-H3 receptor complexes as key targets for reducing cocaine's effects. J Neurosci 34 3545 PMID: 24599455
Jia et al (2013) Age-dependent regulation of synaptic connections by DA D2 receptors. Nat Neurosci 16 1627 PMID: 24121738
Murugan et al (2013) Diminished FoxP2 levels affect DArgic modulation of corticostriatal signaling important to song variability. Neuron 80 1464 PMID: 24268418
Marcellino et al (2008) Identification of DA D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. Front Neurosci 283 26016 PMID: 18644790
Zike (2017) OCD candidate gene SLC1A1/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior. Proc Natl Acad Sci USA 114 5719 PMID: 28507136
Mi (2017) Levo-Tetrahydroberberrubine Produces Anxiolytic-Like Effects in Mice through the 5-HT 1A Receptor. Plos One 12 e0168964 PMID: 28085967
Toro et al (2015) DA Modulates the Activity of Sensory Hair Cells. J Neurosci 35 16494 PMID: 26674873
Herwerth et al (2012) D4 DA receptors modulate NR2B NMDA receptors and LTP in stratum oriens of hippocampal CA1. Cereb Cortex 22 1786 PMID: 21955919
Xing et al (2015) DA D1 receptor activation regulates the expression of the estrogen synthesis gene aromatase B in radial glial cells. Eur J Neurosci 9 310 PMID: 26388722
Polito et al (2015) Selective Effects of PDE10A Inhibitors on Striatopallidal Neurons Require Phosphatase Inhibition by DARPP-32(1,2,3). J Immunol 2 PMID: 26465004
Zhang et al (2018) DA Receptor Subtypes Mediate Opposing Effects on Form Deprivation Myopia in Pigmented Guinea Pigs. Invest Ophthalmol Vis Sci 59 4441 PMID: 30193315
Cilz et al (2014) DArgic modulation of GABAergic transmission in the entorhinal cortex: concerted roles of α1 adrenoreceptors, inward rectifier K+, and T-type Ca2+ channels. Cereb Cortex 24 3195 PMID: 23843440
Burgess et al (2010) DArgic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep 33 1295 PMID: 21061851
Hook et al (2012) DArgic modulation of ganglion-cell photoreceptors in rat. Eneuro 35 507 PMID: 22304466
Prado et al (2012) Stimulation of DA receptor D5 expressed on dendritic cells potentiates Th17-mediated immunity. J Biol Chem 188 3062 PMID: 22379034
Stramiello (2008) D1/5 receptor-mediated enhancement of LTP requires PKA, Src family kinases, and NR2B-containing NMDARs. Neuropharmacology 55 871 PMID: 18644393
Do you know of a great paper that uses SKF 38393 hydrobromide from Tocris? Please let us know.
Reviews for SKF 38393 hydrobromide
There are currently no reviews for this product. Be the first to review SKF 38393 hydrobromide and earn rewards!
Have you used SKF 38393 hydrobromide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.